Kewen W. He

Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

[18F]AlF-NOTA-PCP2 PET/CT to Assess PD-L1 Status in Head and Neck Cancer: Head-to-Head Comparison With [18F]FDG PET/CT.

[18F]AlF-NOTA-PCP2 PET/CT to Assess PD-L1 Status in Head and Neck Cancer: Head-to-Head Comparison With [18F]FDG PET/CT.

Journal: Clinical nuclear medicine

Published: April 10, 2025

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 10, 2024

Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy.

Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy.

Journal: Journal of pharmaceutical analysis

Published: April 08, 2024

Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 08, 2024

Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.

Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.

Journal: Frontiers in oncology

Published: March 26, 2024

Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.

Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 22, 2024

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.

Journal: Melanoma research

Published: June 16, 2023

Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.

Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.

Journal: Molecular oncology

Published: May 19, 2023

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.

Journal: Research square

Published: February 24, 2023

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.

Journal: Cancer immunology, immunotherapy : CII

Published: February 10, 2023

Genomic features, evolutionary patterns and minimal residual disease at surgical margins as novel prognostic/predictive biomarkers in locally advanced rectal cancer.

Genomic features, evolutionary patterns and minimal residual disease at surgical margins as novel prognostic/predictive biomarkers in locally advanced rectal cancer.

Journal: Clinical and translational medicine

Published: January 17, 2023

Strategies to Optimize Treatment for Locally Advanced Rectal Cancer.

Strategies to Optimize Treatment for Locally Advanced Rectal Cancer.

Journal: Cancers

Published: October 30, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026